MCK
A new investor joins the party
Adelphi Trust Co just bought 1,435 shares of McKesson, a position worth about $1.18 million. That’s not exactly a “bet the farm” trade, but it is the kind of move that says, “Yeah, we’re comfortable parking cash here.”
Why this matters
McKesson isn’t a flashy AI darling or a meme-stock roller coaster. It’s a giant healthcare middleman, which means steady money can matter more than drama. When a fund opens a new position, it can signal that the name still looks attractive after a pretty solid run.
The part investors should actually watch
The article also reminds us McKesson just:
- beat quarterly EPS estimates, posting $9.34 vs. $9.19 expected
- delivered $106.16 billion in revenue, up 11.4% year over year
- raised FY2026 guidance to $38.80–$39.20 in EPS
So while Adelphi’s buy is the headline, the bigger story is that McKesson’s fundamentals are still doing their boring-but-beautiful thing.
Big picture
A new institutional stake by itself won’t move a mega-cap much, but it adds to the vibe that investors still like McKesson’s defensive, cash-generating profile. In a market that loves a growth story until it doesn’t, sometimes “solid and unglamorous” wins the day.